decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 2006 OIG Advisory Opinions / Opinion 06-19 - Another PAP Program Approved
Subscribe or sign in to view the full article.
Article Overview
This article summarizes a 2006 Office of Inspector General advisory opinion involving pharmaceutical patient assistance programs for Medicare Part D patients. It explains the general structure of the programs, the eligibility and coordination safeguards described by the OIG, and why the arrangement was viewed as acceptable under the advisory opinion framework. The piece is relevant to compliance professionals, healthcare attorneys, pharmacy stakeholders, and anyone tracking fraud and abuse issues affecting manufacturer assistance programs.
Why This Topic Matters
It helps readers understand how the OIG evaluates manufacturer-sponsored assistance programs that interact with Medicare Part D, including the compliance themes and oversight concerns that drive advisory opinion analysis.
What You Will Learn
- The general purpose and structure of the patient assistance programs discussed in the advisory opinion
- How the opinion fits within Medicare Part D and anti-kickback compliance issues
- What kinds of safeguards and coordination measures were described by the OIG at a high level
- Why pharmaceutical manufacturer assistance programs can raise fraud and abuse concerns
Who Should Read This
- Compliance professionals
- Healthcare attorneys
- Pharmacy benefit stakeholders
- Pharmaceutical manufacturers
- Medicare Part D stakeholders
- Medical coding and reimbursement professionals tracking regulatory guidance
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com